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a b s t r a c t
Background: Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging pathogen that
causes lower respiratory tract infection in humans. Camels are the likely animal source for zoonotic
infection, although exact transmission modes remain to be determined. Human-to-human transmission
occurs sporadically. The wide geographic distribution of MERS-CoV among dromedary camels and ongo-
ing transmissions to humans provides concern for the evolution of a MERS-CoV variant with efﬁcient
human-to-human transmission capabilities. Phylogenetic analysis of MERS-CoV has occurred by analysis
of full-length genomes or multiple concatenated genome fragments, which is time-consuming, costly
and limited to high viral load samples.
Objective: To develop a simple, reliable MERS-CoV variant typing assay to facilitate monitoring of MERS-
CoV diversity in animals and humans.
Study Design: Phylogenetic analysis of presently known full-lengthMERS-CoV genomeswas performed to
identify genomic regions with sufﬁcient phylogenetic content to allow reliableMERS-CoV variant typing.
RT-PCR assays targeting these regions were designed and optimized.
Results: A reverse-transcription PCR assay for MERS-CoV targeting a 615bp spike fragment provides a
phylogenetic clustering of MERS-CoV variants comparable to that of full-length genomes. The detection
limit corresponds to a cycle treshold value of∼35with standard upE real time PCR assays on RNA isolated
from MERS-CoV EMC. Nasal swabs from RT-PCR positive camels (Ct values 12.9–32.2) yielded reliable
sequence information in 14 samples.
Conclusions:Wedevelopeda simple, reliableMERS-CoVvariant typing assaywhich is crucial inmonitoring
MERS-CoV circulation in real time with relatively little investment on location.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Background
Middle East Respiratory Syndrome coronavirus (MERS-CoV; Family
Coronaviridae) may cause severe lower respiratory tract infection
in humans [1,2]. Camels are considered the likely animal source
for zoonotic infection; sporadic human-to-human transmission
does occur, but is considered to be inefﬁcient based on currently
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available data [3–10]. Until recently, new MERS-CoV infections
in humans were reported at a steady low rate reaching ∼200
conﬁrmed human cases early 2014. In March and April 2014, how-
ever, a surge of MERS-CoV infections occurred mainly in hospitals
around Jeddah, Kingdom of Saudi Arabia (KSA) and United Arab
Emirates (UAE). This increased case load was in part attributed to
an increase in community cases, but mostly to transmission within
hospitals, with no evidence for evolution of a MERS-CoV variant
with more efﬁcient human-to-human transmission capabilities
(WHO;http://www.who.int/csr/disease/coronavirus infections/
MERS CoV Update 09 May 2014.pdf?ua=1). The ongoing occur-
rence of new cases, however, and the ﬁnding that MERS-CoV
http://dx.doi.org/10.1016/j.jcv.2014.12.006
1386-6532/© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table 1
Viral genomes used in this study.
Group name Sequences Accession number
RIYADH 9 2013 RIYADH 9 2013 KJ156869
RIYADH 2 2012 KF600652
AL-HASA 15 2013 AL-HASA 19 2013 KF600632
BURAIDAH 1 2013 KF600630
AL-HASA 2 2013 KF186566
AL-HASA 21 2013 KF600634
AL-HASA 25 2013 KJ156866
AL-HASA 17 2013 KF600647
AL-HASA 15 2013 KF600645
AL-HASA 16 2013 KF600644
AL-HASA 12 2013 KF600627
AL-HASA 3 2013 KF186565
AL-HASA 4 2013 KF186564
AL-HASA 18 2013 KF600651
AL-HASA 1 2013 KF186567
AL-HASA 15 2013 KF600645
FRA/UAE 2012 KFU HKU1 2013 KJ650297
KFU HKU19DAM2013 KJ650296
KFU HKU13 2013 KJ650295
FRA/UAE 2012 KF745068
HAFR-AL-BATIN 6 2013 HAFR-AL-BATIN 6 2013 KJ156874
HAFR-AL-BATIN 2 2013 KJ156910
HAFR-AL-BATIN 1 2013 KF600628
RIYADH 5 2013 RIYADH 5 2013 KJ156944
RIYADH 4 2013 KJ156952
TAIF 1 2013 KJ156949
JEDDAH 1 2013 KJ556336
WADI-AD-DAWASIR 1 2013 KJ156881
QATAR 3 2013 QATAR 3 2013 KF961221
QATAR 4 2013 KF961222
RIYADH 1 2012 RIYADH 1 2012 KF600612
BISHA 1 2012 KF600620
RIYADH 3 2013 RIYADH 3 2013 KF600613
Egypt Camel NRCE-HKU205 2014 Egypt Camel NRCE-HKU205 2014 KJ477102
ENGLAND/QATAR 2012 ENGLAND/QATAR 2012 KC667074
EMC 2012 EMC 2012 JX869059
RIYADH 14 2013 RIYADH 14 2013 KJ156934
Munich/AbuDhabi 2013 Munich/AbuDhabi 2013 KF192507
Qatar Camel 2 2014 Qatar Camel 2 2014 KJ650098
JORDAN/N3 2012 JORDAN/N3 2012 KC776174
Not in variant analysis
KSA CAMEL 363 2013 KJ713298
KSA CAMEL 376 2013 KJ713299
KSA Camel 378 2013 KJ713296
KSA CAMEL 503 2013 KJ713297
KSA CAMEL 505 2013 KJ713295
Jeddah Camel 1 2013 KF917527
Jeddah Human 1 2013 KF958702
Florida/USA 2 Saudi Arabia 2014 KJ829365
Indiana/USA-1 Saudi Arabia 2014 KJ813439
is endemic in dromedary camels in a wide geographic region
[3,10,11], stresses the need for surveillance of strain diversity, to
help unravel the epidemiology of this newly identiﬁed pathogen,
and to provide a reference for studies into MERS-CoV evolution.
All currently sequenced human and camel MERS-CoV genomes
share >99% nucleotide identity across the ∼30kb genome. Phy-
logenetic analysis has occurred mainly by analysing full-length
genomes or multiple concatenated genome fragments, to provide
reliable phylogenetic information [5,12–14]. However, full length
genome sequencing capacity is not widely available, and requires
relatively high viral load, leading to limited success when trying to
sequence animal or human samples [5].
2. Objectives
An accurate typing ofMERS-CoV variants, preferablywith a sim-
ple assay encompassing a short region of the MERS-CoV genome,
is crucial in monitoring the MERS-CoV outbreak in real time with
relatively little investments on location. In this study, we describe
the development of a MERS-CoV variant typing assay, which can
be used inmonitoringMERS-CoV circulation, especially whenmore
information on virus type is required rapidly from a large number
of viruses from animals/humans.
3. Study design
3.1. In silico analysis
Full or near full-length MERS-CoV genomes encompassing
nucleotides 215–29770 (numbering corresponding to MERS-
CoV EMC genome JX869059) were aligned with MAFFT ver-
sion 7 (http://mafft.cbrc.jp/alignment/server/) (Table 1). To
remove the redundancy from the dataset, FastGroupII analysis
(http://fastgroup.sdsu.edu/fg tools.htm) was performed grouping
all currently available viral genomes based on nucleotide com-
position, resulting in 15 groups (Table 1). One viral genome
from each group was taken as representative in subsequent anal-
yses. A summary of nucleotide positions that vary across the
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genomes was created using BioEdit v7.2.0 [15] and the number
of nucleotide positions with variations was plotted over 1000
nucleotide windows. PhyML trees were generated using Seaview
4 software with the approximate likelihood ratio test based on
a Shimodaira–Hasegawa-like procedure which used general time
reversible as substitution model. Nearest neighbor interchange,
subtree pruning, and regrafting-based tree search algorithms were
used to estimate tree topologies, as described previously [5].
3.2. MERS-CoV typing RT-PCR
Total nucleic acids were isolated using an automated Mag-
NAPure 96 extraction with the total nucleic acid isolation
kit (Roche, Mannheim, Germany) as described previously [13].
The partial S2 domain of MERS-CoV spike (corresponding to
nucleotides 23781–24395 of MERS-CoV EMC genome JX869059)
was ampliﬁed with the OneStep RT-PCR Kit (Qiagen) using
1x QIAGEN OneStep RT-PCR Buffer, 400M of each dNTP,
2l QIAGEN OneStep RT-PCR Enzyme Mix and 0.6M of
primers VS804 (5′-TCAGGTTGATCAACTTAATAGT-3′) and VS805
(5′-TTGAGTAATGCCAACACCGTT-3′) in a volume of 25l; 30min
50 ◦C, 15min 95 ◦C, 40 cycles of 0.5min 94 ◦C, 0.5min 50 ◦C, 1min
72 ◦C, and a ﬁnal extension of 10min 72 ◦C. A nested PCR was per-
formed using 1x PCR Buffer, 2mM MgCl2, 200M of each dNTP,
20M primers VS804 and VS805 and 2.5 units HotStarTaq DNA
polymerase (Qiagen) in a volume of 50l; 15min 95 ◦C, 40 cycles
of 0.5min 94 ◦C, 0.5min 50 ◦C, 1min 72 ◦C, and a ﬁnal extension of
10min 72 ◦C. Amplicons were sequenced directly on both strands
with the BigDye Terminator version 3.1 cycle sequencing kit on an
ABI PRISM 3100 genetic analyser (Applied Biosystems).
3.3. Samples
The detection limit of the assay was determined on RNA iso-
lated from10xdilutionsof cell culturederivedMERS-CoVEMC 2012
(JX869059), as described above. Virus stocks were prepared as
described previously [16]. RNA was isolated from serial 10-fold
dilutions of MERS-CoV EMC 2012 [13]. Serial 10-fold dilutions of
this RNAwere ampliﬁed in parallel with theMERS-CoV variant typ-
ing assay described above and the upE and N gene real time PCR
assays [17,18]. The sensitivity of theMERS-CoV variant typing assay
was expressed as cycle threshold value based on the upE real time
PCR assay.
On May 13 and 15, 2014, the ﬁrst two MERS-CoV infected
patients in the Netherlands who became infected upon travel to
Saudi Arabia were reported to WHO; throat swabs from these
patients were available [19].
In February and April 2014, nasal swabs were taken from
dromedary camels of different age and sex from a slaughterhouse
in Doha, Qatar [13], which were available for this study.
4. Results
To identify genome regions for reliable phylogenetic analysis
comparable to that of full-length genome, (near) full-length
MERS-CoV genomes (Table 1) were aligned. Viral genomes
that were 99.9% identical were grouped and one viral genome
from each group was taken as representative in the anal-
ysis (Table 1) and a PhyML tree was generated (Fig. 1A).
Four major MERS-CoV clusters can be discerned, represented
by MERS-CoV Qatar 3 2014, England/Qatar 2012, EMC 2012,
and Egypt Camel NRCE-HKU205 2014 (KF961221, KC667074,
JX869059, KJ477102), which have been identiﬁed previously in
analyses based on full-length genomes or concatenated genome
fragments [5,12–14]. The number of single nucleotide polymor-
phisms (SNPs) across the 15 representative MERS-CoV genomes
Fig. 1. CharacterizationofMERS-CoVvariation. (A)PhyML treeof full-lengthgenome
sequences of 15 distinct MERS coronavirus variants based on analysis of nucleotide
sequence diversity across the genome. Four major MERS-CoV clusters are indicated
(A, B1, B2, C). (B) The number of nucleotide positions with variations over 15 rep-
resentative MERS-CoV genomes (Supplementary Table 1) was plotted over 1000
nucleotide windows. A schematic diagram of the MERS-CoV genome is depicted
below the graph, and four fragments with the highest number of single nucleotide
polymorphisms (SNPs) are indicated with black boxes. The dotted line indicates the
average number of SNPs per 1000nt window added with 1x standard deviation. In
red, nucleotide positions displaying considerable phylogenetic information regard-
ing four identiﬁed MERS-CoV variant clusters and the red box indicates the 615bp
fragment of the here-described MERS-CoV variant typing assay. (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
was plotted over 1000nt windows (Fig. 1B). Four genome frag-
ments, two located in ORF1a, one in S and one in ORF4b, showed a
relatively high number of SNPs (Fig. 1B) and for this reason already
had been used as concatenated genome fragment for phylogenetic
analysis [12]. However, phylogenetic trees created for these four
fragments separately did not accurately reﬂect the phylogenetic
positions of the currently known full-length MERS-CoV genomes
(data not shown).
In a subsequent analysis all identiﬁed SNPswere inspected visu-
ally and regions containing SNPs with phylogenetic information
regarding the previously identiﬁed four clusters of viruses were
identiﬁed (Fig. 1A). The S2 domain of the spike protein contains a
number of thesemutations (Fig. 1B). A fragment of 615bp, contain-
ing three of these SNPs, provided a phylogenetic tree similar to the
one obtained upon full-genome analysis regarding the previously
identiﬁed fourMERS-CoV clusters (Fig. 2), whereas otherMERS-CoV
genome regions did not provide similar results. As observed for the
full-length genomes, human, and camelMERS-CoV genomes shared
>99% nucleotide identity across the 615bp S2 domain fragment.
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Fig. 2. Phylogenetic analysis of human and camelMERS-CoVs using theMERS-CoV variant typing assay. A PhyML treewas generated from a spike S2 domain genome fragment
corresponding to nt 23781–24395 ofMERS-CoV EMCgenome (accession number JX869059) for knownMERS-CoV genomes (Table 1) and the ﬁrst twoDutchMERS-CoVpatients
(boxed). In red are newly identiﬁed camel sequences from a slaughterhouse in Qatar. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
MERS-CoVgenomes thatwere released recently andnot takenalong
in the variation analysis were typed using the 615bp S2 domain
and clustered similar to their phylogenetic positions as upon full
genome analysis (Fig. 2 and Table 1), thereby validating the assay.
A sequencing RT-PCR targeting the identiﬁed genome fragment
was developed and optimized using RNA isolated from cell culture-
derived MERS-CoV. In limiting dilution experiments, the MERS-CoV
variant typing assay ampliﬁed the 615bp fragment down to a cycle
tresholdvalueof∼35asdeterminedbydiagnosticupE real timePCR
assays [17,18]. TheMERS-CoV variant typing assaywas used to type
RT-PCR positive nose swabs from the ﬁrst two humanDutchMERS-
CoV cases in 2014. The results showed grouping consistent with
previous ﬁndings based on long sequence fragments [19] (Fig. 2).
In addition, the MERS-CoV variant typing assay was performed on
camel samples from a slaughterhouse in Qatar [13] and sequences
for 14MERS-CoV positive animalswith cycle threshold values rang-
ing from12.9 to32.2 asdeterminedbyUpE real timeRT-PCR [17,18]
were obtained (Fig. 2). Five different camel MERS-CoV variants in
clusters B1 and B2were detected, without the need for full genome
sequencing.
5. Discussion
Phylogenetic analysis of representative MERS-CoV full-length
genomes indicated that four regions in theMERS-CoV genome exist
with a substantially higher nucleotide variation across genomes.
However, phylogenetic analysis of these genome regions sepa-
ratelydidnotprovide reliablephylogenetic information, in contrast
to an analysis of the concatenated fragments [5,12,19]. Subse-
quent analyses revealed a region in the open reading frame that
encodes the spike protein with a number of positions in which
nucleotide variation occurs between MERS-CoV variants with a
strong phylogenetic signal regarding previously identiﬁed clusters
of viruses based on full-length MERS-CoV genomes. The here-
described MERS-CoV variant typing assay based on a 615bp spike
fragmentprovidesacrude indicationof theMERS-CoVvariantunder
study on the basis of four identiﬁed clusters of MERS-CoV vari-
ants, exempliﬁed byMERS-CoVQatar 3 2014, England/Qatar 2012,
EMC 2012, and Egypt Camel NRCE-HKU205 2014. In silico, the
assay accurately typed all currently known MERS-CoVs for which
full-length genomes are available, including the recently released
Florida/USA 2 KSA 2014and Indiana/USA-1 KSA 2014 strains. This
was conﬁrmed by typing of samples available in our laboratory
from the ﬁrst two Dutch MERS-CoV cases that phylogenetically
groupedwith Indiana/USA-1 KSA 2014 and other viruses in cluster
I [19] and from camels from a slaughterhouse in Doha, Qatar [13].
The observed detection limit of a cycle treshold value of∼35 allows
variant typing in clinical samples obtained from humans and ani-
mals with relatively low viral loads. It enables inclusion of samples
in phylogenetic analysis that would not have been included when
only full length genomes would have been accepted.
This MERS-CoV variant typing assay, targeting a part of the
MERS-CoV spike gene, is a relatively simple RT-PCR sequencing
assay that could be performed more widely as initial screening
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assay in laboratories with basic sequencing capacity. It provides
accurate crude MERS-CoV type information, applicable in moni-
toring viral variants in real time. New variants identiﬁed through
this initial screening could then be sent to a reference laboratory
for further characterization. The continued occurrence of trans-
mission between humans in health care and family settings is
an ongoing concern as stated by the World Health Organization
(http://www.who.int/csr/disease/coronavirus infections/MERS
CoV Update 27 March 2014.pdf?ua=1), although the outbreaks
appear to be self-limiting or extinguishable with rigorous imple-
mentation of appropriate infection control guidelines at present.
However, as the primary route of transmission to humans is unin-
terrupted, human-to-human transmissions will continue to occur.
The data obtained from the MERS-CoV variant typing assay would
aid in informing the most effective international preparedness and
response, allowing ad hoc risk assessment and implementation of
containment strategies if necessary.
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